Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EBOS Group Limited ( (AU:EBO) ) has shared an update.
EBOS Group Limited reported its FY25 results, showcasing strong organic growth and strategic execution with a 12% increase in underlying revenue to $12.3 billion and a 7.5% rise in underlying EBITDA to $585 million. The company reinforced its leadership in healthcare and animal care, achieving significant growth in pharmacy wholesale and contract logistics, and expanding its presence in Southeast Asia through acquisitions. The results reflect EBOS’s resilience and strategic positioning in capturing long-term industry trends, with a maintained dividend and confidence in future growth.
The most recent analyst rating on (AU:EBO) stock is a Buy with a A$39.15 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.
More about EBOS Group Limited
EBOS Group Limited is a leading company in the healthcare and animal care sectors, primarily operating as a pharmaceutical wholesaler in Australia and New Zealand. The company is known for its TerryWhite Chemmart network, a community pharmacy network in Australia, and is a significant distributor of medical technology in ANZ and Southeast Asia. In the animal care sector, EBOS operates the largest dry dog food brand in ANZ and is a leading vet wholesaler.
Average Trading Volume: 106,804
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$7.28B
See more data about EBO stock on TipRanks’ Stock Analysis page.